Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats

Reference

• AYRTON, A. and MORGAN, P., 2001, Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica, 31, 469–497.
   PubMed Web of Science ®Google Scholar
• COTREAU, M. M., VON MOLTKE, L. L., HARMATZ, J. S. and GREENBLATT, D. J., 2001, Molecular and pharmacokinetic evaluation of rat hepatic and gastrointestinal cytochrome p450 induction by tamoxifen. Pharmacology, 63, 210–219.
   PubMed Web of Science ®Google Scholar
• DALLAIRE, L., TREMBLAY, L. and BELIVEAU, R., 1991, Purification and characterization of metabolically active capillaries of the blood—brain barrier. Biochemical Journal, 276, 745–752.
   PubMed Web of Science ®Google Scholar
• DENISSEN, J. F., GRABOWSKI, B. A., JOHNSON, M. K., BUKO, A. M., KEMPF, D. J., THOMAS, S. B. and SURBER, B. W., 1997, Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metabolism and Disposition, 25, 489–501.
   PubMed Web of Science ®Google Scholar
• FLEXNER, C., 2000, Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annual Review of Pharmacology and Toxicology, 40, 649–674.
   PubMed Web of Science ®Google Scholar
• FROMM, M. F., 2000, P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. International Journal of Clinical Pharmacology and Therapy, 38, 69-74. GEICK, A., EICHELBAUM, M. and BURR, 0., 2001, Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. Journal of Biological Chemistry, 276, 14581–14587.
   Google Scholar
• GREENBLATT, D. J., VON MOLTKE, L. L., DAILY, J. P., HARMATZ, J. S. and SHADER, R. I., 1999, Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. Journal of Clinical Psychopharmacology, 19, 293–296.
   PubMed Web of Science ®Google Scholar
• GREENBLATT, D. J., VON MOLTKE, L. L., HARMATZ, J. S., DUROL, A. L. B., DAILY, J. P., GRAF, J. A., MERTZANIS, P., HOFFMAN, J. L. and SHADER, R. I., 2000a, Alprazolam—ritonavir interaction: implications for product labeling. Clinical Pharmacology and Therapeutics, 67, 335–341.
   Google Scholar
• GREENBLATT, D. J., VON MOLTKE, L. L., HARMATZ, J. S., DUROL, A. L. B., DAILY, J. P., GRAF, J. A., MERTZANIS, P., HOFFMAN, J. L. and SHADER, R. I., 2000b, Differential impairment of triazolam and zolpidem clearance by ritonavir. Journal of Acquired Immune Deficiency Syndromes, 24, 129–136.
   Google Scholar
• GREENBLATT, D. J., VON MOLTKE, L. L., HARMATZ, J. S., FOGELMAN, S. M., CHEN, G., GRAF, J. A., MERTZANIS, P., BYRON, S., CULM, K. A., GRANDA, B. W., DAILY, J. P. and SHADER, R. I., 2003, Short term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. Journal of Clinical Pharmacology, 43, 414–422.
   PubMed Web of Science ®Google Scholar
• Hsu, A., GRANNEMAN, G. R. and BERTZ, R. J., 1998b, Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clinical Pharmacokinetics, 35, 275–291.
   PubMed Web of Science ®Google Scholar
• Hsu, A., GRANNEMAN, G. R., CAO, G., CAROTHERS, L., EL-SHOURBAGY, T., BAROLDI, P., ERDMAN, K., BROWN, F., SUN, E. and LEONARD, J. M., 1998a, Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clinical Pharmacology and Therapeutics, 63, 453–464.
   Google Scholar
• HUANG, L., WRING, S. A., WOOLLEY, J. L., BROUWER, K. R., SERABJIT-SINGH, C. and POLLI, J. W., 2001, Induction of p-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metabolism and Disposition, 29, 754–760.
   Google Scholar
• JETTE, L., TETU, B. and BELIVEAU, R., 1993, High levels of P-glycoprotein detected in isolated brain capillaries. Biochimica et Biophysica Acta, 1150, 147–154.
   PubMed Web of Science ®Google Scholar
• JONES, S. A., MOORE, L. B., SHENK, J. L., WISELY, G. B., HAMILTON, G. A., McKEE D. D., TOMKINSON, N. C., LECLUYSE, E. L., LAMBERT, M. H., WILLSON, T. M., KLIEWER, S. A. and MOORE, J. T., 2000, The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Molecular Endocrinology, 14, 27–39.
   Google Scholar
• JURANKA, P. F., ZASTAWNY, R. L. and LING, V., 1989, P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB Journal, 3, 2583–2592.
   PubMed Web of Science ®Google Scholar
• KOTEGAWA, T., LAURIJSSENS, B. E., VON MOLTKE, L. L., COTREAU, M. M., PERLOFF, M. D., VENKATAKRISHNAN, K., WARRINGTON, J. S., GRANDA, B. W., HARMATZ, J. S. and GREENBLATT, D. J., 2002, In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. Journal of Pharmacology and Experimental Therapeutics, 302, 1228–1237.
   PubMed Web of Science ®Google Scholar
• KRONBACH, T., MATHYS, D., UMENO, M., GONZALEZ, F. J. and MEYER, U. A., 1989, Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology, 36, 89–96.
   PubMed Web of Science ®Google Scholar
• LECLUYSE, E. L., 2001, Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. Chemico-Biological Interactions, 134, 283–289.
   PubMed Web of Science ®Google Scholar
• LIN, J. H., CHIBA, M., CHEN, I. W., NISHIME, J. A., DELUNA, F. A., YAMAZAKI, M. and LIN, Y. J., 1999, Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3A and p-glycoprotein induction. Drug Metabolism and Disposition, 27, 1187–1193.
   PubMed Web of Science ®Google Scholar
• Luo, G., CUNNINGHAM, M., KIM, S., BURN, T., LIN, J., SINZ, M., HAMILTON, G., Rizzo, C., JOLLEY, S., GILBERT, D., DOWNEY, A., MUDRA, D., GRAHAM, R., CARROLL, K., XIE, J., MADAN, A., PARKINSON, A., CHRIST, D., SELLING, B., LECLUYSE, E. and GAN, L. S., 2002, CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metabolism and Disposition, 30, 795–804.
   PubMed Web of Science ®Google Scholar
• MERRY, C., BARRY, M. G., MULCAHY, F., RYAN, M., HEAVEY, J., TJIA, J. F., GIBBONS, S. E., BRECKENRIDGE, A. M. and BACK, D. J., 1997, Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS, 11, F29—F33.
   PubMed Web of Science ®Google Scholar
• PERLOFF, M. D., VON MOLTKE, L. L. and GREENBLATT, D. J., 2002, Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. Journal of Clinical Pharmacology, 42, 1269–1274.
   PubMed Web of Science ®Google Scholar
• PERLOFF, M. D., VON MOLTKE, L. L. and GREENBLATT, D. J., 2003, Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression. Xenobiotica, 33, 365–377.
   PubMed Web of Science ®Google Scholar
• PERLOFF, M. D., VON MOLTKE, L. L., COURT, M. H., KOTEGAWA, T., SHADER, R. I. and GREENBLATT, D. J., 2000, Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. Journal of Pharmacology and Experimental Therapeutics, 292, 618–628.
   PubMed Web of Science ®Google Scholar
• PERLOFF, M. D., VON MOLTKE, L. L., MARCHAND, J. E. and GREENBLATT, D. J., 2001, Ritonavir induces P-glycoprotein (P-gp) expression, MRP1 expression, and drug transporter-mediated activity in a human intestinal cell line. Journal of Pharmaceutical Sciences, 90, 1829–1837.
   Google Scholar
• PISCITELLI, S. C. and GALLICANO, K. D., 2001, Interactions among drugs for HIV and opportunistic infections. New England Journal of Medicine, 344, 984–996.
   PubMed Web of Science ®Google Scholar
• REGINA, A., ROMERO, I. A., GREENWOOD, J., ADAMSON, P., BOURRE, J. M., COURAUD, P. 0. and Roux, F., 1999, Dexamethasone regulation of P-glycoprotein activity in an immortalized rat brain endothelial cell line, GPNT. Journal of Neurochemistry, 73, 1954–1963.
   Google Scholar
• SADEQUE, A. J., WANDEL, C., HE, H., SHAH, S. and WOOD, A. J., 2000, Increased drug delivery to the brain by P-glycoprotein inhibition. Clinical Pharmacology and Therapeutics, 68, 231–237. SALPHATI, L. and BENET, L. Z., 1998, Modulation of P-glycoprotein expression by Cytochrome P450 3A inducers in male and female rat livers Biochemical Pharmacology, 55, 387–395.
   Google Scholar
• SCHINKEL, A. H., 1999, P-glycoprotein, a gatekeeper in the blood—brain barrier. Advanced Drug Delivery Reviews, 36, 179–194.
   PubMed Web of Science ®Google Scholar
• SCHMIDER, J., GREENBLATT, D. J., VON MOLTKE, L. L., HARMATZ, J. S., DUAN, S. X., KARSOV, D. and SHADER, R. I., 1996, Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. Pharmacology, 52, 125–134.
   PubMed Web of Science ®Google Scholar
• SEGEL, I. H., 1975, Enzyme Kinetics (New York: Wiley).
   Google Scholar
• SHAM, H. L., KEMPF, D. J., MOLLA, A., MARSH, K. C., KUMAR, G. N. et al., 1998, ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrobial Agents and Chemotherapy, 42, 3218–3224.
   Google Scholar
• STöRMER, E., VON MOLTKE, L. L., PERLOFF, M. D. and GREENBLATT, D. J., 2002, Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharmaceutical Research, 19, 1038–1045.
   Google Scholar
• TSENG, A. L. and FOISY, M. M., 1997, Management of drug interactions in patients with HIV. Annals of Pharmacotherapy, 31, 1040–1058.
   PubMed Web of Science ®Google Scholar
• TSUJI, A., TERASAKI, T., TAKABATAKE, Y., TENDA, Y., TAMAI, I., YAMASHIMA, T., MORITANI, S., TSURUO, T. and YAMASHITA, J., 1992, P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sciences, 51, 1427–1437.
   PubMed Web of Science ®Google Scholar
• VAN DE VRIE, W., MARQUET, R. L., STOTER, G., DE BRUIJN, E. A. and EGGERMONT, A. M., 1998, In vivo model systems in P-glycoprotein-mediated multidrug resistance. Critical Reviews of Clinical and Laboratory Sciences, 35, 1–57.
   PubMed Web of Science ®Google Scholar
• VENKATAKRISHNAN, K., VON MOLTKE, L. L., DUAN, S. X., FLEISHAKER, J. C., SHADER, R. I. and GREENBLATT, D. J., 1998, Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. Journal of Pharmacy and Pharmacology, 50, 265–274.
   PubMed Web of Science ®Google Scholar
• VENKATAKRISHNAN, K., von MOLTKE, L. L. and GREENBLATT, D. J., 2001, Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. Journal of Clinical Pharmacology, 41, 1149–1179.
   PubMed Web of Science ®Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., GRASSI, J. M., GRANDA, B. W., DUAN, S. X., FOGELMAN, S. M., DAILY, J. P., HARMATZ, J. S. and SHADER, R. I., 1998, Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. Journal of Clinical Pharmacology, 38, 106–111.
   PubMed Web of Science ®Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., HARMATZ, J. S., DUAN, S. X., HARREL, L. M., COTREAU-BIBBO, M. M., PRITCHARD, G. A., WRIGHT, C. E. and SHADER, R. I., 1996, Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. Journal of Pharmacology and Experimental Therapeutics, 276, 370–379.
   Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., HARMATZ, J. S. and SHADER, R. I., 1993, Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology, 47, 268–276.
   PubMed Web of Science ®Google Scholar
• WARRINGTON, J. S., POKU, J. W., VON MOLTKE, L. L., SHADER, R. I., HARMATZ, J. S. and GREENBLATT, D. J., 2000, Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 292, 1024–1031.
   PubMed Web of Science ®Google Scholar
• YAMAII, H., MATSUMURA, Y., YOSHIKAWA, Y. and TAKADA, K., 1999, Pharmacokinetic interactions between HIV-protease inhibitors in rats. Biopharnzaceutics and Drug Disposition, 20, 241–247.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, M., NEWAY, W. E., OHE, T., CHEN, I., ROWE, J. F., HOCHMAN, J. H., CHIBA, M. and LIN, J. H., 2001, In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. Journal of Pharmacology and Experimental Therapeutics, 296, 723–735.
   PubMed Web of Science ®Google Scholar
• YUMOTO, R., MURAKAMI, T., SANEMASA, M., NASU, R., NAGAI, J. and TAKANO, M., 2001, Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone. Drug Metabolism and Disposition, 29, 145–151.
   PubMed Web of Science ®Google Scholar